Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz gains worldwide marketing rights to Organogenesis' Graftskin.

This article was originally published in The Gray Sheet

Executive Summary

SANDOZ' EXCLUSIVE WORLDWIDE LICENSE TO ORGANOGENESIS' GRAFTSKIN gives the Swiss pharmaceutical company its first medical device product and furthers its expansion into dermatology. The firms jointly announced Jan. 17 an agreement under which Sandoz will pay up to $37.5 mil. in exchange for global marketing rights to Graftskin, a manufactured human skin product for which a premarket approval application is pending at FDA.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005344

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel